ISRCTN22075368已完成未知
Evaluating strategies to delay the emergence of resistance to antimalarial drugs
niversity of Liverpool (UK)0 个研究点目标入组 450 人开始时间: 2005年7月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age more than or equal to 12 and less than 60 months, either sex
- •2. Weight more than or equal to 6 kg
- •3. Pure (on microscopic grounds) P. falciparum parasitaemia of 2000 to 200,000 ul
- •4. Written consent has been obtained from the parent or legal guardian
排除标准
- •1. Severe malaria
- •2. Antimalarials in previous week
- •3. Other comcomitant infection at time of presentation
- •4. Allergy to sulphonamides
- •5. Involvement in the study in the previous 12 months
研究者
相似试验
尚未招募
不适用
10 steps to outrun injury: preventing injuries in runnersNL-OMON27407Erasmus MC University Medical Center Rotterdam, Department of General Practice3,394
进行中（未招募）
1 期
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)EUCTR2011-005219-98-HUGalena Biopharma, Inc700
进行中（未招募）
1 期
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)Operable early-stage, node-positive breast cancerMedDRA version: 19.0Level: LLTClassification code 10071113Term: Node-positive breast cancerSystem Organ Class: 100000004864EUCTR2011-005219-98-BGGalena Biopharma, Inc709
进行中（未招募）
1 期
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)Operable early-stage, node-positive breast cancerMedDRA version: 18.1Level: LLTClassification code 10071113Term: Node-positive breast cancerSystem Organ Class: 100000004864EUCTR2011-005219-98-GBGalena Biopharma, Inc709
进行中（未招募）
1 期
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)EUCTR2011-005219-98-DEGalena Biopharma, Inc709